MARKET

ATAI

ATAI

Atai Beckley Inc
NASDAQ
3.690
+0.050
+1.38%
Pre Market: 3.700 +0.01 +0.27% 05:44 03/05 EST
OPEN
3.730
PREV CLOSE
3.690
HIGH
3.760
LOW
3.595
VOLUME
143
TURNOVER
--
52 WEEK HIGH
6.75
52 WEEK LOW
1.150
MARKET CAP
1.34B
P/E (TTM)
-4.5354
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Atai Beckley N.V. (ATAI)
TipRanks · 1d ago
Analysts Are Bullish on These Healthcare Stocks: Harrow Health (HROW), Atai Beckley N.V. (ATAI)
TipRanks · 1d ago
AtaiBeckley says aligned with FDA on dual-trial design Phase 3 BPL-003 program
TipRanks · 1d ago
AtaiBeckley to Host Virtual Investor Day on BPL-003 Phase 3 Clinical Strategy
Reuters · 1d ago
ATAIBECKLEY INC - ALIGNED WITH FDA ON PHASE 3 PROGRAM FOR BPL-003
Reuters · 1d ago
ATAI Life Sciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
ATAI Life Sciences Price Target Raised to $25.00/Share From $15.00 by HC Wainwright & Co.
Dow Jones · 2d ago
H.C. Wainwright Sticks to Its Buy Rating for Atai Beckley N.V. (ATAI)
TipRanks · 2d ago
More
About ATAI
AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.

Webull offers AtaiBeckley Inc stock information, including NASDAQ: ATAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATAI stock methods without spending real money on the virtual paper trading platform.